Anti-microbial agents and uses thereof
Many pathogens, including Mycobacterium tuberculosis and Yersinia pestis , rely on an iron acquisition system based on siderophores, secreted iron-chelating compounds with extremely high Fe(III) affinity. The compounds of the invention are inhibitors of domain salicylation enzymes, which catalyze the salicylation of an aroyl carrier protein (ArCP) domain to form a salicyl-ArCP domain thioester intermediate via a two-step reaction. The compounds include the intermediate mimic 5′-O—[N-(salicyl)sulfamoyl]-adenosine (salicyl-AMS) and analogs thereof. These compounds are inhibitors of the salicylate activity of MbtA, YbtE, PchD, and other domain salicylation enzymes involved in the biosynthesis of siderophores. Therefore, these compounds may be used in the treatment of infection caused by microorganisms which rely on siderphore-based iron acquisition systems. Pharmaceutical composition and methods of using these compounds to treat or prevent infection are also provided as well as methods of preparing the inventive compounds.
1. A compound of the formula:
wherein:
X is O, S, —CH 2 —, NH, or N—Ac;
A-B is —(R A ) 2 C—C(R B ) 2 —or —R A C═CR B —, wherein each occurrence of R A and R B is independently hydrogen, halogen, cyano, azido, hydroxyl, sulfhydryl, alkoxy, amino, alkylamino, dialkylamino, cyclic or acyclic, unsubstituted or substituted, branched or unbranched aliphatic, cyclic or acyclic, unsubstituted or substituted, branched or unbranched heteroaliphatic, substituted or unsubstituted, branched or unbranched acyl, substituted or unsubstituted, branched or unbranched aryl, substituted or unsubstituted, branched or unbranched heteroaryl; and
L is substituted or unsubstituted, branched or unbranched acyl, or substituted or unsubstituted, branched or unbranched, cyclic or acyclic heteroaliphatic;
or a pharmaceutically acceptable salt thereof.
2. The compound of claim 1 of the formula:
or a pharmaceutically acceptable salt thereof, wherein L′ is substituted or unsubstituted, branched or unbranched, cyclic or acyclic aliphatic; substituted or unsubstituted, branched or unbranched acyl;
or substituted or unsubstituted, branched or unbranched, cyclic or acyclic heteroaliphatic.
3. The compound of claim 1 of the formula:
or a pharmaceutically acceptable salt thereof, wherein n is 0, 1, 2, 3, 4, 5, or 6.
4. The compound of claim 1 of the formula:
or a pharmaceutically acceptable salt thereof, wherein n is 0, 1, 2, 3, or 4; and L′ is substituted or unsubstituted, branched or unbranched, cyclic or acyclic aliphatic; substituted or unsubstituted, branched or unbranched acyl; or substituted or unsubstituted, branched or unbranched, cyclic or acyclic heteroaliphatic.
5. The compound of claim 1 of the formula:
or a pharmaceutically acceptable salt thereof, wherein n is 0, 1, 2, 3, or 4; and L′ is substituted or unsubstituted, branched or unbranched, cyclic or acyclic aliphatic; substituted or unsubstituted, branched or unbranched acyl; or substituted or unsubstituted, branched or unbranched, cyclic or acyclic heteroaliphatic.
6. The compound of claim 1 of the formula:
or a pharmaceutically acceptable salt thereof, wherein:
L′ is substituted or unsubstituted, branched or unbranched, cyclic or acyclic aliphatic;
substituted or unsubstituted, branched or unbranched acyl; or substituted or unsubstituted, branched or unbranched, cyclic or acyclic heteroaliphatic; and
R is hydrogen; halogen; cyclic or acyclic, substituted or unsubstituted, branched or unbranched aliphatic; cyclic or acyclic, substituted or unsubstituted, branched or unbranched heteroaliphatic; substituted or unsubstituted, branched or unbranched acyl; substituted or unsubstituted, branched or unbranched aryl; substituted or unsubstituted, branched or unbranched heteroaryl; —OR′; —C(═O)R′; —CO 2 R′; —CN; —N 3 ; —SCN; —SR′; —SOR'; —SO 2 R′; —NO 2 ; —N(R′) 2 ; —NHC(O)R′; or —C(R′) 3 ; wherein each occurrence of R′ is independently hydrogen, a protecting group, an aliphatic moiety, a heteroaliphatic moiety, an acyl moiety, an aryl moiety, a heteroaryl moiety, alkoxy, aryloxy, alkylthio, arylthio, amino, alkylamino, dialkylamino, heteroaryloxy, or heteroarylthio moiety.
7. The compound of claim 6 of the formula:
or a pharmaceutically acceptable salt thereof.
8. The compound of claim 6 of the formula:
or a pharmaceutically acceptable salt thereof.
9. The compound of claim 6 of formula:
or a pharmaceutically acceptable salt thereof.
10. The compound of claim 9 of formula:
or a pharmaceutically acceptable salt thereof.
11. The compound of claim 9 of formula:
or a pharmaceutically acceptable salt thereof.
12. The compound of claim 1 of formula:
or a pharmaceutically acceptable salt thereof, wherein n is 0, 1, 2, 3, 4, 5, or 6.
13. The compound of claim 1 of formula:
or a pharmaceutically acceptable salt thereof, wherein n is 0, 1, 2, 3, 4, 5, or 6.
14. The compound of claim 1 of formula:
or a pharmaceutically acceptable salt thereof, wherein n is 0, 1, 2, 3, 4, 5, or 6.
15. The compound of claim 1 of the formula:
or a pharmaceutically acceptable salt thereof.
16. A pharmaceutical composition comprising a compound of claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.
17. The pharmaceutical composition of claim 16 comprising approximately 1 mg to approximately 500 mg of the compound.
18. The pharmaceutical composition of claim 16 suitable for treating an infection.
19. A method of treating a subject infected with a microorganism comprising administering to the subject a therapeutically effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt thereof.
20. The compound of claim 1 of the formula:
or a pharmaceutically acceptable salt thereof, wherein R is hydrogen; halogen; cyclic or acyclic, substituted or unsubstituted, branched or unbranched aliphatic; cyclic or acyclic, substituted or unsubstituted, branched or unbranched heteroaliphatic; substituted or unsubstituted, branched or unbranched acyl; substituted or unsubstituted, branched or unbranched aryl; substituted or unsubstituted, branched or unbranched heteroaryl; —OR′; —C(═O)R′; —CO 2 R′; —CN; —N 3 ; —SCN; —SR′; —SOR′; —SO 2 R′; —NO 2 ; —N(R′) 2 ; —NHC(O)R′; or —C(R′) 3 ; wherein each occurrence of R′ is independently hydrogen, a protecting group, an aliphatic moiety, a heteroaliphatic moiety, an acyl moiety, an aryl moiety, a heteroaryl moiety, alkoxy, aryloxy, alkylthio, arylthio, amino, alkylamino, dialkylamino, heteroaryloxy, or heteroarylthio moiety.
21. The compound of claim 1 of the formula:
or a pharmaceutically acceptable salt thereof, wherein:
L′ is substituted or unsubstituted, branched or unbranched, cyclic or acyclic aliphatic; substituted or unsubstituted, branched or unbranched acyl; or substituted or unsubstituted, branched or unbranched, cyclic or acyclic heteroaliphatic;
each occurrence of R is independently hydrogen; halogen; cyclic or acyclic, substituted or unsubstituted, branched or unbranched aliphatic; cyclic or acyclic, substituted or unsubstituted, branched or unbranched heteroaliphatic; substituted or unsubstituted, branched or unbranched acyl; substituted or unsubstituted, branched or unbranched aryl; substituted or unsubstituted, branched or unbranched heteroaryl; —OR′; —C(═O)R′; —CO 2 R′; —CN; —N 3 ; —SCN; —SR′; —SOR′; —SO 2 R′; —NO 2 ; —N(R′) 2 ; —NHC(O)R′; or —C(R′) 3 ; wherein each occurrence of R′ is independently hydrogen, a protecting group, an aliphatic moiety, a heteroaliphatic moiety, an acyl moiety, an aryl moiety, a heteroaryl moiety, alkoxy, aryloxy, alkylthio, arylthio, amino, alkylamino, dialkylamino, heteroaryloxy, or heteroarylthio moiety; and
n is 0, 1, 2, 3, or 4.
22. The compound of claim 1 of the formula:
or a pharmaceutically acceptable salt thereof.
23. The compound of claim 1 of the formula:
or a pharmaceutically acceptable salt thereof, wherein n is 0 or 1.
24. The compound of any one of claims 2 , 4 - 11 , and 22 , wherein L′ is of the formula:
wherein n is 0, 1, 2, 3, 4, 5, or, 6.
25. The method of claim 19 , wherein the microorganism is Yersinia pestis or Yersinia enterocolitica.
26. The method of claim 19 , wherein the microorganism is Mycobacterium tuberculosis.
27. The method of claim 19 , wherein the microorganism is selected from the group consisting of Pseudomonas aeruginosa , Acinetobacter calcoaceticus, Acinetobacter baumannii, Escherichia coli, Salmonella enterica, Shigella spp., Vibrio anguillarum , and Vibrio cholerae.
28. The compound of any one of claims 2 , 4 - 11 , and 22 , wherein L′ is of the formula:
wherein n is 0, 1, 2, 3, 4, 5, or, 6.